Rank #1: June 2019: If the drugs don’t work
Read the full issue: https://dtb.bmj.com/content/57/6.
May 29 2019
Rank #2: May 2019: The new GP contract - an opportunity for drugs and therapeutics
Read the issue online: https://dtb.bmj.com/content/57/5.
May 15 2019
Rank #3: April 2019: DOAC dosing in renal impairment
Read the issue online: https://dtb.bmj.com/content/57/4.
Mar 20 2019
Rank #4: March 2019: A new direction for diabetes
Read the full issue: https://dtb.bmj.com/content/57/3.
Feb 25 2019
Rank #5: February 2019: The past, present and future of inhaled corticosteroids for COPD
Read the full issue: https://dtb.bmj.com/content/57/2
Jan 21 2019
Rank #6: January 2019: Challenging the supremacy of intravenous antibiotics
Read the issue: dtb.bmj.com/content/57/1.
Dec 14 2018
Rank #7: December 2018: Information on medicines for patients
Read the issue: https://dtb.bmj.com/content/56/12.
Nov 16 2018
Rank #8: October 2018: atrial fibrillation, opioids for chronic pain and over-the-counter sildenafil
The editors also consider problems associated with long-term opioid use in the management of chronic pain (https://dtb.bmj.com/content/56/10/118). Please watch the video about Michael's moving story on this subject at dtb.bmj.com.
The launch of slidenafil as an over-the-counter pharmacy medicine (https://dtb.bmj.com/content/56/10/123) is also discussed.
Read the latest from the reinvented Drug and Therapeutics Bulletin here: dtb.bmj.com.
Oct 08 2018
Rank #9: Here's your New DTB!
The editors also consider the place for monitored dosage systems (https://dtb.bmj.com/content/56/9/102) and discuss the evidence for using labetalol as a first-line treatment option for hypertension in pregnancy (https://dtb.bmj.com/content/56/9/107).
Meet the new DTB here: https://dtb.bmj.com/content/56/9.
Sep 12 2018
Rank #10: August 2018: what’s your position on giving birth?
Read the editorial: https://dtb.bmj.com/content/56/8/85.
The editors also consider nutritional support in primary care (https://dtb.bmj.com/content/56/8/90) and discuss new licensing pathways that provide faster access to medicines (https://dtb.bmj.com/content/56/8/93).
Aug 06 2018
Rank #11: July 2018: managing herbal-drug interactions
Read the editorial: https://dtb.bmj.com/content/56/7/73.
The editors also review the evidence for ocrelizumab for relapsing MS and early primary progressive MS (https://dtb.bmj.com/content/56/7/80), and discuss the role of metformin in people with type 1 diabetes (https://dtb.bmj.com/content/56/7/78).
Jul 11 2018
Rank #12: June 2018: Antidepressants - there is no news
The editors also review the evidence for the combination analgesic of tramadol/dexketoprofen (dtb.bmj.com/content/56/6/66), and question the dose of paracetamol for older people (dtb.bmj.com/content/56/6/69).
Jul 02 2018
Rank #13: May 2018: Does pulmonary rehabilitation need more PR?
The editors also review the evidence for safinamide for Parkinson’s disease (http://dtb.bmj.com/content/56/5/54), and discuss the use of bezlotoxumab, a monoclonal antibody licensed for the prevention of recurrence of Clostridium difficile infection in adults who are at high risk of recurrence (http://dtb.bmj.com/content/56/5/57).
May 09 2018
Rank #14: April 2018: STOMP - time to make more noise
Read the article: http://dtb.bmj.com/content/56/4/37.
The editors also review the evidence for a once-daily triple inhaler for maintenance treatment for adults with moderate to severe COPD (http://dtb.bmj.com/content/56/4/42), and discuss off-label use of high-dose antihistamines for chronic spontaneous urticaria in adults (http://dtb.bmj.com/content/56/4/45).
Apr 11 2018
Rank #15: March 2018: Do hypertension guidelines put the person first?
The editors also review the evidence for dupliumab for the treatment of moderate-to-severe atopic dermatitis in adults (http://dtb.bmj.com/content/56/3/30) and discuss drug names (http://dtb.bmj.com/content/56/3/33).
Read the full March 2018 issue here: http://dtb.bmj.com/content/56/3.
Mar 12 2018
Rank #16: February 2018: Clinical guidelines - more PDAs please
The editors also review the evidence for cladribine for the treatment of highly active relapsing multiple sclerosis (http://dtb.bmj.com/content/56/2/21) and discuss the latest levonorgestrel IUS device to be marketed for contraception (http://dtb.bmj.com/content/56/2/18).
Feb 09 2018
Rank #17: January 2018: No alchemy for obesity
The editors also review the evidence for ▼patiromer, a cation exchange polymer, that has recently been marketed for the management of hyperkalaemia - http://dtb.bmj.com/content/56/1/6 and discuss the management of gout. http://dtb.bmj.com/content/56/1/9
Jan 02 2018
Rank #18: September 2017: Vitamin D and adolescents: a forgotten ‘at risk’ group?
The editors also review the management of scarlet fever (http://dtb.bmj.com/content/55/9/102.2) and consider two drugs (baricitinib and tofacitinib) recently licensed for the management of rheumatoid arthritis (http://dtb.bmj.com/content/55/9/102.1).
Sep 04 2017
Rank #19: June 2017: Turning the tide of high-dose inhaled corticosteroids
The editors also highlight some of the challenges associated with the management of superficial venous thrombosis of the leg and discuss the use of carbohydrate deficient transferrin as a biomarker for the assessment of chronic alcohol use.
Read more about the DTB's June 2017 issue: http://dtb.bmj.com/content/55/6#DTBSelect.
Jun 05 2017
Rank #20: May 2017: Rational rationing in the NHS?
The editors also review the evidence for the use of off-label testosterone supplementation in menopausal women (http://dtb.bmj.com/content/55/5/57) and discuss a new formulation of the topical antiseptic dequalinium (http://dtb.bmj.com/content/55/5/54) that is licensed for treatment of bacterial vaginosis.
May 03 2017